199 related articles for article (PubMed ID: 16027168)
41. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors.
Simpkins SB; Peiffer-Schneider S; Mutch DG; Gersell D; Goodfellow PJ
Gynecol Oncol; 1998 Dec; 71(3):391-5. PubMed ID: 9887237
[TBL] [Abstract][Full Text] [Related]
42. [Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer].
Zhang L; Liu T; Liu H; Gao J; Gu C
Zhonghua Bing Li Xue Za Zhi; 2000 Apr; 29(2):85-8. PubMed ID: 11866895
[TBL] [Abstract][Full Text] [Related]
43. PTEN mutations are common in sporadic microsatellite stable colorectal cancer.
Nassif NT; Lobo GP; Wu X; Henderson CJ; Morrison CD; Eng C; Jalaludin B; Segelov E
Oncogene; 2004 Jan; 23(2):617-28. PubMed ID: 14724591
[TBL] [Abstract][Full Text] [Related]
44. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.
Marsit CJ; Zheng S; Aldape K; Hinds PW; Nelson HH; Wiencke JK; Kelsey KT
Hum Pathol; 2005 Jul; 36(7):768-76. PubMed ID: 16084946
[TBL] [Abstract][Full Text] [Related]
45. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
[TBL] [Abstract][Full Text] [Related]
46. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
47. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation.
Liu JL; Sheng X; Hortobagyi ZK; Mao Z; Gallick GE; Yung WK
Mol Cell Biol; 2005 Jul; 25(14):6211-24. PubMed ID: 15988030
[TBL] [Abstract][Full Text] [Related]
48. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma.
Marsh J; Mukherjee P; Seyfried TN
Clin Cancer Res; 2008 Dec; 14(23):7751-62. PubMed ID: 19047102
[TBL] [Abstract][Full Text] [Related]
49. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
50. grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten+/- mice.
Cully M; Elia A; Ong SH; Stambolic V; Pawson T; Tsao MS; Mak TW
Proc Natl Acad Sci U S A; 2004 Oct; 101(43):15358-63. PubMed ID: 15492213
[TBL] [Abstract][Full Text] [Related]
51. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.
Davies MA; Kim SJ; Parikh NU; Dong Z; Bucana CD; Gallick GE
Clin Cancer Res; 2002 Jun; 8(6):1904-14. PubMed ID: 12060635
[TBL] [Abstract][Full Text] [Related]
52. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang SI; Parsons R; Ittmann M
Clin Cancer Res; 1998 Mar; 4(3):811-5. PubMed ID: 9533551
[TBL] [Abstract][Full Text] [Related]
53. The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002.
Fernandez M; Eng C
Clin Cancer Res; 2002 Jun; 8(6):1695-8. PubMed ID: 12060605
[TBL] [Abstract][Full Text] [Related]
54. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness.
Kotelevets L; van Hengel J; Bruyneel E; Mareel M; van Roy F; Chastre E
J Cell Biol; 2001 Dec; 155(7):1129-35. PubMed ID: 11756467
[TBL] [Abstract][Full Text] [Related]
55. PTEN deficiency: a role in mammary carcinogenesis.
Petrocelli T; Slingerland JM
Breast Cancer Res; 2001; 3(6):356-60. PubMed ID: 11737885
[TBL] [Abstract][Full Text] [Related]
56. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas.
Kurose K; Zhou XP; Araki T; Eng C
Genes Chromosomes Cancer; 2000 Oct; 29(2):166-72. PubMed ID: 10959096
[TBL] [Abstract][Full Text] [Related]
57. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.
Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Genes Chromosomes Cancer; 2002 Sep; 35(1):74-80. PubMed ID: 12203792
[TBL] [Abstract][Full Text] [Related]
58. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
59. Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases.
Hahn M; Wieland I; Koufaki ON; Görgens H; Sobottka SB; Schackert G; Schackert HK
Clin Cancer Res; 1999 Sep; 5(9):2431-7. PubMed ID: 10499615
[TBL] [Abstract][Full Text] [Related]
60. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
